Work

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng

Year: 2023

Type: article

Abstract: To the Editor: We thank Dr Meng for the thoughtful letter further elaborating on the possible significance of NLRC5 polymorphisms in the development of immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) and other immune-related adverse events (irAEs). Dr Meng further highlights a

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1136/jitc-2023-007397

Authors: Lilach Aizenbud, David A Schoenfeld, Jasmine I Caulfield, Jacqueline E Mann, Matthew R Austin, Ana Luisa Perdigoto, Kevan C Herold, Harriet M Kluger

Institution: Yale University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

Funders: Bristol-Myers Squibb, Yale University, Celldex Therapeutics, Shionogi, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: G1044130170, G1358700859, Cytoplasmic cyclin E is an early event for progression to invasive breast cancer, G3276807266, G3586022433, G3968055098, G633865952, G9000059311, G9000070285, G9000078561, Yale Clinical and Translational Science Award

OpenAlex ID: W4381715740

FWCI:

Cites: 6

Cited by:

Related to: 10